FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

GSK collaborates on immune disease research

GlaxoSmithKline has inked a five year, $25 million collaboration deal with the Disease Institute of Boston to conduct on immunoinflammation research. GSK and IDI researchers will develop joint grant proposals in targeted areas of research under an Alliance Research grant program. GSK gets first dibs on any drug targets identified through the collaboration.

"GSK is committed to becoming a world leader within 3 years in drug discovery of immuno-inflammation," said Jose Carlos Gutierrez-Ramos, head of the Immuno-Inflammation Center of Excellence for Drug Discovery of GSK. "This agreement fits perfectly with our strategy to pursue scientific excellence and technologies both internally and externally."

- see GSK's release for more

Related Articles:
GSK successful in Phase III inflammation trial
GSK shakes up R&D
GSK heralds biotech drug development model

More stories about GlaxoSmithKline   Phase III   inflammatory diseases   Boston  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 18 + 39?
To combat spam, please solve the math question above.